July 9, 2015.
The European Association of BioIndustries, EuropaBio, has called on policymakers to remove the hurdles preventing European patients’ access to personalized medicine (PM).
At the EU’s “Making Access to Personalised Medicine a Reality for Patients” conference yesterday, the Association repeated its argument that biopharma companies face high costs of clinical development for regulatory approval against a backdrop of increasingly fragmented reimbursement systems and assessment mechanisms unfit for the specificities of personalized therapies.
EuropaBio’s recent White Paper on Personalised Medicine identifies the "essential changes needed to successfully integrate personalized medicine approaches into existing healthcare systems".
Hugh Pullen, Chair of the EuropaBio Task Force on Personalized Medicine, commented: “[W]e wish to see a concrete action plan within the adaptive pathways pilot program focused on speeding up PM regulatory approval. In addition, there is a need for HTA agencies to better collaborate on defining value assessment framework for personalized medicine to accelerate progress in the field. Finally, the implementation of measures to monitor the concrete uptake of personalized medicine in the Member States is overdue.”
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.